[HTML][HTML] Novel treatment strategies for early-stage lung cancer: the oncologist's perspective
A Indini, E Rijavec, C Bareggi… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Management of early-stage non-small cell lung cancer (NSCLC) consists in multimodal
treatment, including surgery, radiotherapy and chemotherapy. The mainstay of treatment is …
treatment, including surgery, radiotherapy and chemotherapy. The mainstay of treatment is …
[HTML][HTML] Real-world survival outcomes based on EGFR mutation status in Chinese patients with lung adenocarcinoma after complete resection: results from the ICAN …
XN Yang, HH Yan, J Wang, XY Chu, ZD Liu… - JTO clinical and …, 2022 - Elsevier
Introduction The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD)
remains unstandardized. We analyzed the survival outcomes of these patients based on …
remains unstandardized. We analyzed the survival outcomes of these patients based on …
Making adjuvant therapy decisions with uncertain data
1. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatchrepair deficiency.
N Engl J Med 2015; 372 (26): 2509–2520. 2. Gerlinger M, Rowan AJ, Horswell S et al …
N Engl J Med 2015; 372 (26): 2509–2520. 2. Gerlinger M, Rowan AJ, Horswell S et al …
[HTML][HTML] Genetic alteration profile of EGFR-mutant resected IIB–IIIA stage NSCLC and correlation to clinical outcomes
Q Deng, Y Qiu, J Jia, H Tang, L Liu… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background Genetic alteration profile of epidermal growth factor receptor (EGFR) mutant
resected non-small cell lung cancer (NSCLC) and its relationship with clinical outcomes …
resected non-small cell lung cancer (NSCLC) and its relationship with clinical outcomes …
[HTML][HTML] Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
Z Zeng, B Yan, Y Chen, L Zhang, J Zhu… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) are increasing considered for the tailored management of resectable non-small cell …
(TKIs) are increasing considered for the tailored management of resectable non-small cell …
[HTML][HTML] Адъювантная таргетная терапия при немелкоклеточном раке легкого
КК Лактионов, АМ Казаков, МГ Гордиев… - Современная …, 2020 - cyberleninka.ru
Немелкоклеточный рак легкого (НМРЛ) является гетерогенной группой заболеваний с
широким спектром возможных таргетных активирующих мутаций. В связи с этим на …
широким спектром возможных таргетных активирующих мутаций. В связи с этим на …
Application of mutant enrichment technologies to improve the clinical sensitivity of plasma epidermal growth factor receptor testing in non-small cell lung cancer …
김보연 - 2021 - ir.ymlib.yonsei.ac.kr
Worldwide, the incidence of lung cancer continues to increase, and it is the most common
cause of cancer death. 1 Non-small cell lung cancer (NSCLC), a heterogeneous class of …
cause of cancer death. 1 Non-small cell lung cancer (NSCLC), a heterogeneous class of …
Adjuvant targeted therapy for non-small cell lung cancer
KK Laktionov, AM Kazakov… - Journal of Modern …, 2020 - modernonco.orscience.ru
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases with a wide
range of possible targeted activating mutations. In this regard, a lot of attention is paid to …
range of possible targeted activating mutations. In this regard, a lot of attention is paid to …